摘要
背景:据估计,从确诊阿尔茨海默病(AD)到患者死亡的平均时间为 5-9 年。因此,无论是疾病的初始阶段还是临床前状态,都可以纳入疾病诊断的关键期。因此,最近在生物标志物研究方面取得了巨大进展,以识别具有正常认知功能和轻度认知障碍的老年人痴呆症的危险因素。 方法:电化学生物传感器是一种优秀的分析工具,用于检测 AD 生物标志物,因为它们易于使用、便携且可以进行实时分析。 结果:这篇综述介绍了目前用于确定 AD 生物标志物的分析技术的优缺点; AD 最重要的临床生物标志物及其在疾病中的作用。首次总结了电化学生物传感器开发中最近使用的所有生物识别分子,即受体蛋白、抗体、适体和核酸。还回顾了用于 AD 生物标志物检测的新型电化学生物传感器,作为即时诊断的理想分析平台。 结论:本文重点介绍了生物传感器化学表面修饰的各种策略,以固定生物识别分子,从而在合成和临床样本中实现特异性、定量的 AD 生物标志物检测。此外,这是第一次介绍基于电化学技术同时检测多种生物标志物和其他重要 AD 相关生物物种的创新单平台系统。讨论了这些平台在疾病诊断中的重要性。
关键词: 阿尔茨海默病、生物标志物检测、早期诊断、生物传感器、表面改性、多重检测。
Current Medicinal Chemistry
Title:Recent Advancements in Electrochemical Biosensors for Alzheimer’s Disease Biomarkers Detection
Volume: 28 Issue: 20
关键词: 阿尔茨海默病、生物标志物检测、早期诊断、生物传感器、表面改性、多重检测。
摘要:
Background: It is estimated that the average time between the diagnosis of Alzheimer’s disease (AD) and the patient’s death is 5-9 years. Therefore, both the initial phase of the disease and the preclinical state can be included in the critical period in disease diagnosis. Accordingly, huge progress has recently been observed in biomarker research to identify risk factors for dementia in older people with normal cognitive functions and mild cognitive impairments.
Methods: Electrochemical biosensors are excellent analytical tools that are used in the detection of AD biomarkers as they are easy to use, portable, and can do analysis in real time.
Results: This review presents the analytical techniques currently used to determine AD biomarkers in terms of their advantages and disadvantages; the most important clinical biomarkers of AD and their role in the disease. All recently used biorecognition molecules in electrochemical biosensor development, i.e., receptor protein, antibodies, aptamers and nucleic acids, are summarized for the first time. Novel electrochemical biosensors for AD biomarker detection, as ideal analytical platforms for point-of-care diagnostics, are also reviewed.
Conclusion: The article focuses on various strategies of biosensor chemical surface modifications to immobilize biorecognition molecules, enabling specific, quantitative AD biomarker detection in synthetic and clinical samples. In addition, this is the first review that presents innovative single-platform systems for simultaneous detection of multiple biomarkers and other important AD-associated biological species based on electrochemical techniques. The importance of these platforms in disease diagnosis is discussed.
Export Options
About this article
Cite this article as:
Recent Advancements in Electrochemical Biosensors for Alzheimer’s Disease Biomarkers Detection, Current Medicinal Chemistry 2021; 28 (20) . https://dx.doi.org/10.2174/0929867327666201111141341
DOI https://dx.doi.org/10.2174/0929867327666201111141341 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HSP27: Mechanisms of Cellular Protection Against Neuronal Injury
Current Molecular Medicine Challenges in Neuronal Apoptosis
Current Alzheimer Research ADAM10 as a Therapeutic Target for Cancer and Inflammation
Current Pharmaceutical Design 1, 2-Benzisoxazole: A Privileged Structure with a Potential for Polypharmacology
Current Pharmaceutical Design Advances in Sickle Cell Disease Treatment: from Drug Discovery Until the Patient Monitoring
Cardiovascular & Hematological Agents in Medicinal Chemistry Modulation of Retinal Arteriolar Central Reflection by APOE Genotype
Current Alzheimer Research Hydroxypyridinone Derivatives: A Fascinating Class of Chelators with Therapeutic Applications - An Update
Current Medicinal Chemistry Neuropsychiatric Systemic Lupus Erythematosus
Current Neuropharmacology Homocysteine in Neurological Disease: A Marker or a Cause?
CNS & Neurological Disorders - Drug Targets Mediterranean Diet, Brain and Muscle: Olive Polyphenols and Resveratrol Protection in Neurodegenerative and Neuromuscular Disorders
Current Medicinal Chemistry Predementia and Dementia Syndromes: Possible Role of Lipoprotein Metabolism
Vascular Disease Prevention (Discontinued) Cognitive Impairment in Depression
Current Psychiatry Reviews Measuring Alzheimer Disease Progression with Transition Probabilities: Estimates from NACC-UDS
Current Alzheimer Research Impact of MRI-based Segmentation Artifacts on Amyloid- and FDG-PET Quantitation
Current Alzheimer Research Bleeding Complications in the Course of Treatment with Antidepressants in Elderly Patients
Current Psychiatry Reviews Dysregulated NF-κB Pathway in Peripheral Mononuclear Cells of Alzheimers Disease Patients
Current Alzheimer Research Quantitative Electroencephalogram Analysis in Parkinson’s Disease
Neuroscience and Biomedical Engineering (Discontinued) Oxidative Stress Modulation Through Habitual Physical Activity
Current Pharmaceutical Design Disease Modifying Approaches for Alzheimers Pathology
Current Pharmaceutical Design Role of Inflammatory Markers in Elderly Type 2 Diabetic Patients with Mild Cognitive Impairment
Current Diabetes Reviews